Merck (MRK) Issues Positive Update on KEYTRUDA Phase 2 in Colorectal Cancer, Other Solid Tumors
Tweet Send to a Friend
Merck (NYSE: MRK) announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE